Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion .
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues. mylan stock buy or sell
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings. Management expects roughly 2% total revenue growth and
To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) mylan stock buy or sell
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).